

# HRT and heavy-handed headlines: do new studies change anything?

*Controversy surrounding the pros and cons of hormone replacement therapy (HRT) has been exacerbated recently by a study suggesting it may increase the risk of ovarian and breast cancers,<sup>1</sup> and a reopened debate on its cardiovascular effects.<sup>2</sup> Nick Panay considers the implications for treatment of menopausal symptoms*



**Nick Panay** BSc MRCOG MFFP

Director  
West London Menopause & PMS Centre  
Queen Charlotte's and Chelsea & Westminster  
Hospitals

As director of the Menopause and PMS Centre at Queen Charlotte's Hospital, Nick heads a busy clinical and research team. As Council Member of the British Menopause Society, Adviser to Women's Health Concern and Chairman of the National Association for Premenstrual Syndrome, Nick campaigns for women's health issues nationally and internationally

UNTIL FIVE YEARS ago, hormone replacement therapy (HRT) was used by more than one-third of postmenopausal women for symptoms and prophylaxis against the long-term sequelae of the menopause. However, as a result of adverse publicity on the possible risks of HRT (breast and cardiovascular) arising from publication of the Women's Health Initiative (WHI) and Million Women studies (MWS) in 2002/03, there was a significant downturn in HRT usage, which dropped by up to 50% in some countries.<sup>5-6</sup>

The last couple of years had seen stabilisation of usage following recent favourable data on cardiovascular and breast cancer risks and life expectancy.<sup>7</sup> Encouraged by clinicians and the menopause societies, around one-third of the women who came off their HRT asked to restart because of a return of their symptoms.<sup>8</sup>

Most recently, menopausal women and their GPs have been confronted with further confusing data and the resultant media headlines. First, falling breast cancer rates in some areas of the USA were equated to falling HRT usage rates since 2002.<sup>9</sup> This extrapolation was criticised by the menopause societies, who pointed out that the fall in rates may not have been in ex-HRT users; rates were starting to fall prior to 2002 anyway, and this may have occurred because less women were attending for breast-screening, having come off HRT.

In April 2007, data from the reanalysis of the joint data from the combined and estrogen-alone WHI studies were published. These data showed that there was no increase in coronary heart disease (CHD) risk for the youngest cohort of participating women (50-59 years) and a 30% decrease in all-cause mortality, significant at the  $p < 0.05$  level.<sup>2</sup> These data supported

the concept that HRT does not cause harm, and may even be protective, when given to younger women in whom the arterial endothelium is still intact.<sup>10</sup>

A few weeks later, further news came from the MWS, which suggested that HRT may increase the risk of ovarian cancer diagnosis and mortality. The data were alarmingly represented by Cancer Research UK and the media as the total number of ovarian cancer cases (1,300) linked to HRT usage over 14 years. Data were only collected for five years from 1996-2001 by the MWS but, controversially, extrapolation was carried out using HRT usage rates from 1991-2005. The absolute risk was rather less alarming at one case per 2,500 users and one death per 3,300 users.<sup>1</sup> The observational questionnaire methodology of the MWS once again came in to question, as the randomised prospective WHI study had not indicated a problem with ovarian cancer.

## Regulatory authorities and societies

Although the regulatory authorities, eg, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, and the European Agency for the Evaluation of Medicinal Products (EMA) still advocate the use of HRT, they stipulate that it should be at the minimum effective dose for the shortest possible duration with annual re-evaluation. The guidelines have not changed since October 2004 but, following the most recent data, the MHRA have indicated that there will be a re-evaluation of the guidelines, which will be released in the next few months.

## Changes in prescribing of HRT and alternative therapies

New data suggest that the benefits of HRT can be maintained with lower doses than

previously used while minimising risks and possibly side effects. A recent study showed preservation of osteogenic benefits at a dose as low as 0.5 mg of 17 $\beta$  oestradiol.<sup>11</sup> The importance of androgen replacement is also evolving, with the recent licensing of the first transdermal testosterone preparation for surgically menopausal women with distressing low libido.

There has also been a move towards alternative therapies, eg, complementary medicines such as phytoestrogens. This is a largely unregulated area, with products that often have little or no efficacy and questionable safety – for instance, there have been recent reports of liver failure in users of Black Cohosh. However, there are more promising data for some red clover and soy products.<sup>12</sup>

### Key take-home messages

Despite the most recent new data, current best practice has not significantly changed since the author's previous publication,<sup>13</sup> and should involve the following:

- ❖ Discussion of lifestyle measures, HRT and alternatives should take place from the outset.
- ❖ Management should be individualised, taking into account risks and benefits.
- ❖ The main indication for HRT should be for symptom relief, rather than for the prevention of long-term problems, until we have better data on primary prevention.
- ❖ Low-dose HRT should usually be commenced, except in premature ovarian failure, and increased if necessary to achieve effective symptom relief.
- ❖ Rigid cutoffs in duration of therapy should be avoided, with regular reappraisal (at least annual) of the benefits and risks for each individual.
- ❖ Delivery of services should be from a multidisciplinary team if possible, with close liaison with allied specialities and experts. ❖

### REFERENCES

1. Beral V, Bull D, Green J, Reeves G, the Million Women Study Collaborators. Ovarian cancer and hormone replacement therapy in the Million Women Study. *Lancet* 2007;369(9574):1703-10.
2. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007;297(13):1465-77.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen



- plus progestin in healthy postmenopausal women: principal results from Women's Health Initiative randomized controlled trial. *JAMA* 2002;288(3):321-33.
4. Million Women Study Collaborators. Breast cancer and HRT in the Million Women Study. *Lancet* 2003;362:419-27.
5. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004;291(14):1701-12.
6. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. *Lancet* 2005;365:1543-51.
7. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med* 2004;19(7):791-804.
8. Genazzani AR, Schneider HP, Panay N, Nijland EA. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. *Gynecol Endocrinol* 2006;22(7):369-75.
9. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. *N Engl J Med* 2007;356:1670-74.
10. On behalf of The Board of The International Menopause Society: Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS Updated Recommendations on

postmenopausal hormone therapy. *Climacteric* 2007;10(3):181-94.

11. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. *Climacteric* 2007;10(2):120-31.
12. Panay N, Rees M. *The use of alternatives to HRT for the management of menopause symptoms*. Royal College of Obstetricians and Gynaecologists (RCOG) Scientific Advisory Committee Opinion Paper 6. May 2006. Available from: <http://www.rcog.org.uk/index.asp?PageID=1561>
13. Panay N. The menopause and HRT: where are we now? *The New Generalist* 2005;3(4):16-19.

### RESOURCES

**British Menopause Society**  
[www.thebms.org.uk](http://www.thebms.org.uk)

**International Menopause Society**  
[www.imsociety.org](http://www.imsociety.org)

**Medicines and Healthcare products Regulatory Agency**  
[www.mhra.gov.uk](http://www.mhra.gov.uk)

**Menopause Matters**  
[www.menopausematters.co.uk](http://www.menopausematters.co.uk)

**National Osteoporosis Society**  
[www.nos.org.uk](http://www.nos.org.uk)

**North American Menopause Society**  
[www.menopause.org](http://www.menopause.org)